Form Type:  8-K
Filing Date:  4/13/2022 
CIK:  0000939767 
Address:  1851 HARBOR BAY PARKWAY 
City, State, Zip:  ALAMEDA, California 94502 
Telephone:  (650) 837-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.06 (-0.34%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
Trade EXEL now with

© 2023  
Description of Business
Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care. Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S.
Register and access this filing in:     
  FORM 8-K
      Item 5.02 Departure of Directors or Certain Officers; ...

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.